Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study | Zendy

James C. Yao | Zendy; Alexandria T. Phan | Zendy; David Z. Chang | Zendy; Robert A. Wolff | Zendy; Kenneth R. Hess | Zendy; Sanjay Gupta | Zendy; Carmen Jacob | Zendy; Jeannette E. Mares | Zendy; Andrea Landgraf | Zendy; Asif Rashid | Zendy; Funda MericBernstam | Zendy

Open Access

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

Author(s) -

James C. Yao,

Alexandria T. Phan,

David Z. Chang,

Robert A. Wolff,

Kenneth R. Hess,

Sanjay Gupta,

Carmen Jacob,

Jeannette E. Mares,

Andrea Landgraf,

Asif Rashid,

Funda MericBernstam

Publication year - 2008

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2008.16.7858

Subject(s) - medicine , octreotide , gastroenterology , everolimus , neuroendocrine tumors , chromogranin a , carcinoid syndrome , progressive disease , biopsy , urology , surgery , chemotherapy , somatostatin , immunohistochemistry

Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research